Anteris Technologies Global, an Australia-based maker of artificial heart valves, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company's shares are currently listed on the Australian Securities Exchange under the symbol "AVR."
Anteris is a structural heart company focused on patients with aortic stenosis. Its lead product, the DurAVR transcatheter heart valve (THV) system, consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR? balloon-expandable delivery system. To date, a total of 73 patients have been treated with the DurAVR THV system across the US, Canada, and Europe.
The Toowong, Australia-based company was founded in 1999 and booked $3 million in revenue for the 12 months ended September 30, 2024. It plans to list on the Nasdaq under the symbol AVR. Anteris Technologies Global filed confidentially on February 14, 2024. TD Cowen, Barclays, and Cantor Fitzgerald are the joint bookrunners on the deal. No pricing terms were disclosed.
